These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32510625)

  • 21. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study.
    Liu J; Fan Z; Xu N; Ye J; Chen Y; Shao R; Sun Y; Wu Q; Liu Q; Jin H
    Ann Hematol; 2023 Oct; 102(10):2865-2877. PubMed ID: 37474631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party.
    Penack O; Peczynski C; Boreland W; Lemaitre J; Afanasyeva K; Kornblit B; Jurado M; Martinez C; Natale A; Pérez-Simón JA; Brunello L; Avenoso D; Klein S; Ozkurt ZN; Herrera C; Wichert S; Chiusolo P; Gavriilaki E; Basak GW; Schoemans H; Koenecke C; Moiseev I; Peric Z
    Front Immunol; 2023; 14():1283034. PubMed ID: 38149251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
    Fan S; Huo WX; Yang Y; Shen MZ; Mo XD
    Front Immunol; 2022; 13():954268. PubMed ID: 35990629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
    Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.
    Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L
    Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
    Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
    Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
    [No Abstract]   [Full Text] [Related]  

  • 27. C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation.
    Minculescu L; Kornblit BT; Friis LS; Schiødt I; Petersen SL; Andersen NS; Sengeloev H
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):600-607. PubMed ID: 29074374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.
    Kitko CL; Braun T; Couriel DR; Choi SW; Connelly J; Hoffmann S; Goldstein S; Magenau J; Pawarode A; Reddy P; Schuler C; Yanik GA; Ferrara JL; Levine JE
    Biol Blood Marrow Transplant; 2016 May; 22(5):862-8. PubMed ID: 26551636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
    Teshima T; Onishi Y; Kato K; Taniguchi S; Miyamura K; Fukushima K; Kato J; Ishikawa T; Doki N; Nakamae H; Maeda Y; Inamoto Y; Okada M; Maki A; Shimada F; Tajima T; Wroclawska M; Zeiser R; Onizuka M
    Int J Hematol; 2024 Jul; 120(1):106-116. PubMed ID: 38796666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network.
    Alousi AM; Weisdorf DJ; Logan BR; Bolaños-Meade J; Carter S; Difronzo N; Pasquini M; Goldstein SC; Ho VT; Hayes-Lattin B; Wingard JR; Horowitz MM; Levine JE;
    Blood; 2009 Jul; 114(3):511-7. PubMed ID: 19443659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ruxolitinib Combined with Corticosteroids as First-Line Therapy for Acute Graft-versus-Host Disease in Haploidentical Peripheral Blood Stem Cell Transplantation Recipients.
    Hou C; Dou L; Jia M; Li F; Wang S; Gao X; Wang L; Jin X; Wang L; Gao C; Liu D
    Transplant Cell Ther; 2021 Jan; 27(1):75.e1-75.e10. PubMed ID: 32961370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience.
    De Jong CN; Saes L; Klerk CPW; Van der Klift M; Cornelissen JJ; Broers AEC
    PLoS One; 2017; 12(10):e0187184. PubMed ID: 29073260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
    Przepiorka D; Luo L; Subramaniam S; Qiu J; Gudi R; Cunningham LC; Nie L; Leong R; Ma L; Sheth C; Deisseroth A; Goldberg KB; Blumenthal GM; Pazdur R
    Oncologist; 2020 Feb; 25(2):e328-e334. PubMed ID: 32043777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
    Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmeister CC; Benson DM; Penza S; Elder P; Cortright K; Kitzler R; Coombes K; O'Donnell L; Daneault B; Bradbury H; Zhang J; Chen X; Garman S; Ranganathan P; Yu X; Hofstetter J; Yu J; Garzon R; Scrape SR; Lozanski G; Devine SM
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):71-9. PubMed ID: 26256940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
    Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
    Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ruxolitinib add-on in corticosteroid-refractory graft-
    Dang SH; Liu Q; Xie R; Shen N; Zhou S; Shi W; Liu W; Zou P; You Y; Zhong ZD
    World J Clin Cases; 2020 Mar; 8(6):1065-1073. PubMed ID: 32258077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
    Zeiser R; von Bubnoff N; Butler J; Mohty M; Niederwieser D; Or R; Szer J; Wagner EM; Zuckerman T; Mahuzier B; Xu J; Wilke C; Gandhi KK; Socié G;
    N Engl J Med; 2020 May; 382(19):1800-1810. PubMed ID: 32320566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis.
    Hui L; Qi L; Guoyu H; Xuliang S; Meiao T
    Expert Rev Hematol; 2020 May; 13(5):565-575. PubMed ID: 32178541
    [No Abstract]   [Full Text] [Related]  

  • 39. A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis.
    Morozova EV; Barabanshikova MV; Moiseev IS; Shakirova AI; Barhatov IM; Ushal IE; Rodionov GG; Moiseev SI; Surkova EA; Lapin SV; Vlasova JJ; Rudakova TA; Darskaya EI; Baykov VV; Alyanski AL; Bondarenko SN; Afanasyev BV
    Acta Haematol; 2021; 144(2):158-165. PubMed ID: 32325461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: A single-center pediatric series.
    Rosa M; Jarmoliński T; Miśkiewicz-Migoń I; Liszka K; Miśkiewicz-Bujna J; Panasiuk A; Frączkiewicz J; Ussowicz M
    Adv Clin Exp Med; 2022 Mar; 31(3):345-350. PubMed ID: 35212198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.